- Peter Kinder resigns federal agency post, concludes position unnecessary and waste of tax dollars (6/16/18)2
- Committee to start planning process for indoor aquatic center in Cape (6/20/18)1
- Judge denies order of protection for woman accusing deputy of stalking her (6/23/18)5
- Longtime downtown Cape bartender Marcellus Jones remembered by friends (6/12/18)2
- Southeast to spend $150,000 to refresh brand with Ohio firm (6/19/18)6
- Stooges in Jackson under new ownership (6/23/18)
- Poplar Bluff nail manufacturer gets hammered by new tariffs on steel (6/22/18)7
- Stormy Daniels to visit East Cape Girardeau (6/13/18)20
- Scott County Sheriff Wes Drury responds to issue involving deputy (6/23/18)2
- Neal Boyd blessed us all with his God-given talent (6/19/18)
Senate blocks bid to allow prescription drug imports
WASHINGTON -- The Senate effectively killed a bid to allow consumers to buy their prescription medicines abroad Monday, requiring U.S. officials to certify the safety and effectiveness of such drugs.
The certification amendment, passed on a 49-40 vote, would require health officials to do something they have long said they cannot.
Because of that, the vote undercut a second measure that would permit prescription drug imports from Food and Drug Administration-approved sources in Canada, Australia, Europe, Japan and New Zealand.
The Bush administration opposes allowing imports of prescription drugs, and the White House had threatened a veto.
Sen. Bernie Sanders, I-Vt., called the certification amendment, introduced by Sen. Thad Cochran, R-Miss., a "poison pill" for the drug-imports legislation. Sen. Byron Dorgan, D-N.D., acknowledged it voided his bid to allow the purchase of drugs abroad.
Overseas, drugs can cost two-thirds less than they do in the United States, where prices for brand-name drugs are among the highest in the world.
Allowing imports from those countries would drive down U.S. brand-name drug prices, Dorgan has said.
Both the Cochran and Dorgan measures were amendments to broader FDA legislation.
The idea of allowing prescription drug imports enjoys broad popular support. However, lower prices overseas would not automatically translate into large savings for domestic consumers, according to a 2004 study by the Congressional Budget Office.
The study found that allowing drug imports from a broad set of countries would cut U.S. drug spending by $40 billion over 10 years, about a 1 percent savings.
The pharmaceutical industry vehemently opposes allowing drug imports, arguing that they could leave the nation vulnerable to dangerous counterfeits.
Similar drug-import legislation is pending in the House.